Postpartum haemorrhage (PPH) is a leading cause of maternal mortality, globally, disproportionately affecting low and middle-income countries (LMICs). It also contributes significanlty to maternal morbidity and long-term disability. Preventing PPH is essential for improving maternal health outcomes and can be prevented to a large extent through the administration of a quality-assured, effective uterotonic immediately following child birth.
Access to quality, effective lifesaving uterotonics in LMICs remains a barrier to reducing maternal deaths from PPH. The objective of this study was to assess the costs of care for women who receive different preventative uterotonics, and with PPH and no-PPH so that the differences, if significant, can inform better resource allocation for maternal health care.